How Methandrostenolone (Dianabol) Affects HDL Cholesterol

Methandrostenolone suppresses HDL via two competing mechanisms, the balance of which determines its net lipid impact:

1. Hepatic lipase (HTGL) upregulation via first-pass metabolism: As a 17-AA oral, methandrostenolone delivers a concentrated androgenic load to hepatocytes on first pass, upregulating HTGL and accelerating HDL catabolism. This is the same mechanism as stanozolol and other orals.
2. ApoA-I suppression: Reduces synthesis of the primary structural protein of HDL particles.
3. Partial estrogenic counterbalance via aromatisation: Methandrostenolone aromatises heavily to estradiol. Estradiol suppresses HTGL gene expression (Jones 2002) and supports ApoA-I production. This estrogenic activity partially offsets the direct androgenic HTGL stimulation, which is why Dianabol produces less severe HDL suppression than stanozolol (which does not aromatise at all).
4. Net effect: Despite the estrogenic buffer, the first-pass hepatic androgenic stimulus overwhelms the partial estrogenic protection, still resulting in clinically significant HDL suppression. The estrogenic offset makes Dianabol less lipid-toxic than stanozolol or oxymetholone per mg, but it does not render it lipid-safe.

Important nuance: This means that aggressive aromatase inhibitor (AI) use during a Dianabol cycle removes the partial lipid protection from aromatisation, making the lipid impact worse than it would be if estradiol were allowed to remain in a reasonable range.

At 20-40 mg/day (moderate bodybuilding doses):

• Significant HDL suppression: typically 30-50% from baseline
• A pre-cycle HDL of 50 mg/dL might fall to 25-35 mg/dL
• LDL often rises simultaneously

At 50+ mg/day:

• Severe HDL suppression: 50-70%+ from baseline is possible
• HDL may fall below 20 mg/dL in users with pre-existing lipid sensitivity

Kickstart context (4-6 weeks):

• Dianabol is most commonly used as a 4-6 week kickstart at the beginning of a longer injectable cycle. Limiting use to this duration reduces cumulative exposure but does not eliminate the lipid damage during the kickstart period.

Stacking amplification: Combining Dianabol with trenbolone or stanozolol produces additive lipid damage beyond either compound alone.

Baseline lipid panel before starting:

• Essential reference point before adding any oral compound

On cycle:

• Check lipids at week 4 (typically the end of a kickstart period)
• If continuing the oral beyond 4-6 weeks, recheck at week 8

Post-cycle:

• Recheck lipids 4 weeks after stopping the oral component
• Recovery is typically faster after Dianabol cessation than after trenbolone cessation

During cycle:

• Limit use to 4-6 weeks as a kickstart; longer oral use increases cumulative lipid risk
• Do not stack with other hepatotoxic 17-AA orals (stanozolol, anadrol); the lipid and liver damage are additive
• Avoid aggressive AI use: crashing estradiol removes the partial HDL protection from aromatisation. Allow estradiol to remain in a reasonable range (20-40 pg/mL); this is preferable from both a lipid and symptom management perspective.
• Cardiovascular exercise 30-45 minutes, 4-5 times per week
• Omega-3 fatty acids 3-4 g EPA/DHA daily
• Citrus bergamot 500-1000 mg/day

Cycle design:

• If using Dianabol, favour shorter cycles with longer recovery periods. The 4-6 week oral kickstart into a longer injectable cycle is more lipid-conservative than running Dianabol throughout.